STOCK TITAN

Tyra Biosciences (TYRA) 10-K Filings

TYRA NASDAQ

Here are the 10-K annual reports from Tyra Biosciences, Inc. (TYRA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow TYRA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TYRA filings page.

Rhea-AI Summary

Tyra Biosciences is a clinical-stage biotechnology company developing next‑generation precision small molecules focused on fibroblast growth factor receptor (FGFR) biology, using its in‑house SNÅP structure‑guided drug design platform.

The lead asset is oral dabogratinib (formerly TYRA‑300), an FGFR3‑selective inhibitor in three Phase 2 programs: SURF303 for low‑grade upper tract urothelial carcinoma, SURF302 for intermediate‑risk non‑muscle invasive bladder cancer, and BEACH301 for achondroplasia in children. The company plans potential registrational trials if Phase 2 data are successful and holds orphan drug and rare pediatric disease designations for achondroplasia.

Additional programs include TYRA‑430, an FGFR4/3‑biased inhibitor in a Phase 1 trial for FGF19‑positive hepatocellular carcinoma, and TYRA‑200, an FGFR1/2/3 inhibitor in Phase 1 for FGFR2‑driven intrahepatic cholangiocarcinoma resistant to prior FGFR therapy. Tyra reports a robust patent estate extending into the 2040s and relies on third‑party manufacturers while retaining global development and commercialization rights to all pipeline assets.

As of June 30, 2025, non‑affiliate common stock market value was approximately $297.3 million, and as of February 25, 2026, there were 53,867,115 shares outstanding.